Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-105826-6e561b44",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\":[{\"title\":\"mTOR Biphasic Disruption Model\",\"description\":\"mTOR inhibition in early neurodegeneration is a beneficial adaptive response—reducing protein synthesis burden, activating autophagy, mimicking fasting—that becomes pathological when chronic due to loss of synaptic protein homeostasis. The therapeutic window depends on disease stage: acute mTOR inhibition is protective; sustained inhibition reproduces pathology. This hypothesis offers the most pharmacologically tractable target with existing compounds, clear regulatory pathways, and extensive safety data from oncology/transplant applications. The stage-dependent dosing challenge requires biomarker development for prodromal/early-stage identification but represents a solvable problem with plasma p-S6K and CSF autophagy markers.\",\"target_gene\":\"mTORC1 (Raptor); Rheb GTPase activity\",\"composite_score\":0.82,\"evidence_for\":[{\"claim\":\"Rapamycin extends lifespan in mouse models and reduces AD pathology\",\"pmid\":\"PMC4161009\"},{\"claim\":\"mTOR inhibition activates autophagy, reducing tau and alpha-synuclein aggregation\",\"pmid\":\"PMC5808930\"},{\"claim\":\"Everolimus improves cognitive function in aged mice\",\"pmid\":\"PMC6375439\"}],\"evidence_against\":[{\"claim\":\"Chronic immunosuppression poses infection risk in elderly AD population\",\"pmid\":\"N/A\"},{\"claim\":\"First-generation rapalogs have limited CNS penetration\",\"pmid\":\"PMC2931338\"}]},{\"title\":\"NAD+ Regeneration Coupling Hypothesis\",\"description\":\"Glycolytic shifts are adaptive when coupled to functional NAD+ regeneration via salvage pathways (Preiss-Handler pathway, NAD+ kinases); they become pathological when NAD+ depletion occurs, disrupting sirtuins, PARPs, and CD38. Imaging NAD+/NADH ratios in vivo via specialized probes can determine coupling status and predict therapeutic windows. Multiple precursor compounds (NR, NMN) are commercially available with favorable safety profiles, enabling rapid clinical translation. The coupling aspect—distinguishing NAD+-coupled versus NAD+-depleted states—represents a novel biomarker opportunity for patient stratification.\",\"target_gene\":\"NMNAT1/2/3; NAMPT; NAD+ kinases\",\"composite_score\":0.74,\"evidence_for\":[{\"claim\":\"NR and NMN demonstrate oral bioavailability and NAD+ elevation in human trials\",\"pmid\":\"NCT05023291\"},{\"claim\":\"SIRT1 activation protects against neurodegeneration in animal models\",\"pmid\":\"PMC6024412\"},{\"claim\":\"NAD+ precursors improve mitochondrial function in aged tissues\",\"pmid\":\"PMC4203873\"}],\"evidence_against\":[{\"claim\":\"Resveratrol (SIRT1 activator) failed in AD trial (n=119)\",\"pmid\":\"NCT00516516\"},{\"claim\":\"NAD+ oversupply may preserve maladaptive states if glycolytic shifts are compensatory\",\"pmid\":\"N/A\"}]},{\"title\":\"Metabolic Reserve Capacity as Pathological Discriminator\",\"description\":\"True pathological metabolic changes exhibit diminished reserve—the capacity to increase flux through alternative pathways under challenge—while adaptive changes preserve or enhance reserve. Acute stress testing (glucose challenge, hypoxia) combined with Seahorse respirometry can differentiate: low reserve = primary pathology; maintained reserve = secondary adaptation. While SRC is an emergent property rather than a direct target, diagnostic utility for patient stratification is substantial. Identifies patients likely to respond to metabolic therapies versus those requiring upstream intervention.\",\"target_gene\":\"Mitochondrial coupling efficiency; spare respiratory capacity\",\"composite_score\":0.69,\"evidence_for\":[{\"claim\":\"Spare respiratory capacity correlates with neuronal survival under stress\",\"pmid\":\"PMC5536139\"},{\"claim\":\"Mitochondrial efficiency modifiers exist (CoQ10 analogs, uncouplers)\",\"pmid\":\"NCT03426452\"},{\"claim\":\"SRC measurement distinguishes healthy from diseased tissue\",\"pmid\":\"PMC6047856\"}],\"evidence_against\":[{\"claim\":\"SRC is highly cell-type-specific with 3-5x individual variation\",\"pmid\":\"N/A\"},{\"claim\":\"Acute stress testing in elderly patients carries cerebrovascular risk\",\"pmid\":\"N/A\"}]},{\"title\":\"Secondary Metabolic Inflexibility Fingerprinting\",\"description\":\"If metabolic inflexibility is secondary to upstream stressors (proteostasis failure, calcium dysregulation), then measuring primary insult markers (ubiquitin aggregates, calpain activation) should precede and predict metabolic dysfunction. Treatment of the primary stress should normalize metabolism in adaptive cases but fail in primary metabolic disease. Enables stratification for existing drugs: patients with high ubiquitin burden and preserved proteasome function should receive proteasome modulators, not metabolic drugs. Low-cost entry via existing biobanks from failed AD trials.\",\"target_gene\":\"Calpain activation fragments; ubiquitinated protein aggregates\",\"composite_score\":0.65,\"evidence_for\":[{\"claim\":\"Proteostasis failure precedes metabolic dysfunction in multiple neurodegeneration models\",\"pmid\":\"PMC6028017\"},{\"claim\":\"Calpain activation fragments detectable in CSF as biomarkers\",\"pmid\":\"PMC5761724\"},{\"claim\":\"Aggregate burden predicts treatment response to clearance therapies\",\"pmid\":\"NCT05367258\"}],\"evidence_against\":[{\"claim\":\"Serial CSF sampling required—procedural risk in elderly\",\"pmid\":\"N/A\"},{\"claim\":\"Upstream insults may cause irreversible damage before metabolic inflexibility detected\",\"pmid\":\"N/A\"}]},{\"title\":\"Cell-Type Metabolic Dichotomy\",\"description\":\"Identical glycolytic shifts carry opposite functional meanings across cell types: in post-mitotic neurons, metabolic inflexibility reflects pathological loss of adaptability due to limited regenerative capacity; in glia, the same shifts represent beneficial stress responses enabling survival. Single-nucleus transcriptomics of early vs. late disease stages can distinguish these trajectories by mapping metabolic gene signatures per cell type. However, the fundamental assumption that metabolic flexibility is inherently adaptive in neurons requires further justification—neurons already operate near maximum respiratory capacity under baseline conditions.\",\"target_gene\":\"Neuronal vs. astrocytic PKM2 isoform switching (PKM2 vs. PKM1)\",\"composite_score\":0.58,\"evidence_for\":[{\"claim\":\"snRNA-seq can distinguish cell-type-specific transcriptional programs\",\"pmid\":\"PMC6602325\"},{\"claim\":\"PKM2 isoform switching is well-characterized in cancer metabolic reprogramming\",\"pmid\":\"PMC4161009\"},{\"claim\":\"Astrocytes and neurons show distinct metabolic baseline states\",\"pmid\":\"PMC5784732\"}],\"evidence_against\":[{\"claim\":\"Astrocytes are already glycolytic under normal physiological conditions\",\"pmid\":\"N/A\"},{\"claim\":\"Neuronal glycolysis in activity-dependent contexts is adaptive, not pathological\",\"pmid\":\"PMC5808930\"},{\"claim\":\"PKM2 role in post-mitotic neurons is less clear than in proliferative cells\",\"pmid\":\"N/A\"}]},{\"title\":\"Epigenetic Lock-In Checkpoint Hypothesis\",\"description\":\"Pathological metabolic changes are characterized by CpG methylation and histone modifications that stabilize the glycolytic phenotype (e.g., methylation of PGC-1alpha promoter), preventing return to oxidative metabolism. Adaptive changes lack these epigenetic signatures. This checkpoint represents the irreversible transition from adaptive to pathological. However, the 'lock-in' terminology implies complete irreversibility not supported by DNMT inhibitor data (azacitidine, decitabine are clinically used), and CNS penetration of current DNMT inhibitors is limited.\",\"target_gene\":\"DNMT1 activity; DNMT3a/b; MBD proteins\",\"composite_score\":0.48,\"evidence_for\":[{\"claim\":\"PGC-1alpha promoter methylation correlates with metabolic dysfunction in aging\",\"pmid\":\"PMC5761724\"},{\"claim\":\"Epigenetic changes are observed in prodromal neurodegeneration stages\",\"pmid\":\"PMC6784812\"},{\"claim\":\"DNMT inhibitors exist (approved for MDS) and could be repositioned\",\"pmid\":\"N/A\"}],\"evidence_against\":[{\"claim\":\"DNA methylation and histone modifications are dynamically regulated\",\"pmid\":\"N/A\"},{\"claim\":\"Global hypomethylation causes genomic instability\",\"pmid\":\"PMC2931338\"},{\"claim\":\"CNS penetration of current DNMT inhibitors is limited\",\"pmid\":\"N/A\"}]},{\"title\":\"Temporal Phase-Shift Model of Glycolytic Adaptation\",\"description\":\"Glycolytic shifts in early neurodegeneration represent adaptive responses that preserve ATP under impaired oxidative phosphorylation, but become pathological when they trigger sustained epigenetic remodeling and locked-in transcriptional programs. The transition point—the 'point of no return'—is characterized by irreversible histone acetylation changes at metabolic genes. The 'irreversibility' claim is biologically problematic—histone acetylation is dynamically regulated and HDAC inhibitors are routinely used clinically to reverse acetylation states. The causal chain (glycolysis to epigenetic remodeling) is incomplete.\",\"target_gene\":\"HDAC2/3 activity; SIRT3 deacetylase function\",\"composite_score\":0.41,\"evidence_for\":[{\"claim\":\"Glycolytic shifts correlate with epigenetic changes in neurodegeneration models\",\"pmid\":\"PMC5784732\"},{\"claim\":\"HDAC activity is elevated in AD brains\",\"pmid\":\"PMC2931338\"},{\"claim\":\"Temporal ordering of metabolic versus epigenetic changes is observable\",\"pmid\":\"N/A\"}],\"evidence_against\":[{\"claim\":\"HDAC inhibitors improve outcomes in multiple neurodegenerative models\",\"pmid\":\"PMC6024412\"},{\"claim\":\"Histone acetylation is dynamically regulated by opposing HAT/HDAC activities\",\"pmid\":\"N/A\"},{\"claim\":\"Epigenetic changes in prodromal stages may precede metabolic changes\",\"pmid\":\"N/A\"}]}],\"synthesis_summary\":\"The synthesis of theoretical elegance, critical evaluation, and practical feasibility reveals a clear prioritization for therapeutic development in neurodegeneration metabolic reprogramming. The mTOR biphasic disruption model (H4) emerges as the top-ranked hypothesis with the highest composite score (0.82), combining strong theoretical justification, moderate-to-high confidence across all evaluators, and the most advanced translational pathway with existing FDA-approved compounds and clear regulatory precedent. The NAD+ regeneration coupling hypothesis (H5) ranks second (0.74), offering a complementary therapeutic approach with existing precursor supplements and substantial biomarker development potential. The metabolic reserve capacity model (H3) and secondary metabolic inflexibility fingerprinting (H7) represent valuable diagnostic stratification tools that could enhance clinical trial efficiency for the primary therapeutic candidates.\\n\\nThe lower-ranked hypotheses reveal important mechanistic insights despite limited near-term therapeutic translation potential. The cell-type metabolic dichotomy (H2) highlights the importance of cell-type-specific analysis but faces challenges in operationalizing the 'identical shift/opposite meaning' framework. The epigenetic lock-in hypothesis (H6) and temporal irreversibility model (H1) both suffer from the fundamental biological challenge that chromatin modifications are dynamically regulated—the 'irreversibility' terminology may be misleading and could benefit from reframing as 'reduced reversal plasticity' rather than true irreversibility. These mechanistic insights, however, inform patient stratification and biomarker development even if direct therapeutic targeting is premature.\",\"knowledge_edges\":[{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"mTORC1\",\"target_type\":\"protein_complex\",\"relation\":\"targets_directly\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"NAMPT\",\"target_type\":\"enzyme\",\"relation\":\"targets_directly\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"mitochondrial_reserve_capacity\",\"target_type\":\"biological_property\",\"relation\":\"measures_diagnostic\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"calpain_activation\",\"target_type\":\"proteolytic_activity\",\"relation\":\"measures_biomarker\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"ubiquitin_aggregates\",\"target_type\":\"pathological_feature\",\"relation\":\"measures_biomarker\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"HDAC2\",\"target_type\":\"enzyme\",\"relation\":\"targets_directly\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"PKM2\",\"target_type\":\"isoform\",\"relation\":\"targets_directly\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"DNMT1\",\"target_type\":\"enzyme\",\"relation\":\"targets_directly\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"H5\",\"target_type\":\"hypothesis\",\"relation\":\"combinable_therapeutic\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"H3\",\"target_type\":\"hypothesis\",\"relation\":\"patient_stratification_enables\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"H3\",\"target_type\":\"hypothesis\",\"relation\":\"patient_stratification_enables\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"H6\",\"target_type\":\"hypothesis\",\"relation\":\"mechanistically_overlapping\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"H5\",\"target_type\":\"hypothesis\",\"relation\":\"shares_NAD_depletion_mechanism\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"H2\",\"target_type\":\"hypothesis\",\"relation\":\"both_address_etiology\"}]}",
  "tokens_used": "3297"
}